Specifically, Dupixent is approved to treat moderate to severe asthma that is either: dependent on treatment with an oral corticosteroid, or eosinophilic (caused by an increase in eosinophils ...

The FDA is to review Sanofi/Regeneron's Dupixent as a treatment for asthma, a new use that could more than double its sales following its previous approval for eczema. Analysts predict peak annual ...

According to the lawsuit, Sanofi has failed to provide partner Regeneron adequate information regarding the sales of Dupixent ...

Dupixent (dupilumab) is a brand-name injectable drug prescribed for asthma, eczema ... When you start Dupixent treatment, you and your doctor will discuss which form (pen or syringe) is right ...

Immunology superstar Dupixent, which first brought Regeneron and Sanofi together in 2007, has entered its megablockbuster era ...

The final appraisal document for Dupixent (dupilumab ... in five people with suspected severe asthma are not being referred to specialists for the treatments that could transform, and even ...

US FDA Approves Dupixent Injections For People Struggling ... “This could be a game-changer for people with asthma and COPD. Treatment for asthma and COPD exacerbations have not changed in ...

But with good asthma treatment, most people can do almost anything ... Examples include Xolair, Dupixent, and Nucala.

Sanofi in partnership with Regeneron to present 24 abstracts across approved and investigational medicines at AAAAI Annual Meeting in San Diego: Paris Friday, February 7, 2025, 12 ...

GSK plc has announced that new drug applications have been accepted for review by the China National Medical Products ...

Following receipt of dupilumab for 24 weeks, desensitization to peanut exposure in most children/adolescents with peanut ...